ストックスクリーナーアプリを入手
5.96
2.76%
0.16
プレマーケット:
5.95
-0.010
-0.17%
前日終値:
$5.80
開ける：
$5.88
24時間の取引高:
416.49K
Relative Volume:
0.47
時価総額：
$467.98M
収益：
$531.00K
当期純損益:
$-99.96M
株価収益率:
-2.7191
EPS:
-2.1919
ネットキャッシュフロー:
$-98.96M
1週間 パフォーマンス:
+2.58%
1か月 パフォーマンス:
+4.20%
6か月 パフォーマンス:
-27.32%
1年 パフォーマンス:
+33.93%
1日の値動き範囲:
$5.74
$6.03
1週間の範囲:
$5.54
$6.03
52週間の値動き範囲:
$2.43
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
名前
Lexeo Therapeutics Inc
セクター
電話
(212) 547-9879
住所
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
5.96 | 467.98M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Raymond James | Strong Buy |
| 2025-11-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-10-15 | 開始されました | Guggenheim | Buy |
| 2025-07-31 | 開始されました | Oppenheimer | Outperform |
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-06-06 | 開始されました | H.C. Wainwright | Buy |
| 2023-11-28 | 開始されました | Chardan Capital Markets | Buy |
| 2023-11-28 | 開始されました | JP Morgan | Overweight |
| 2023-11-28 | 開始されました | Leerink Partners | Outperform |
| 2023-11-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-11-28 | 開始されました | Stifel | Buy |
すべてを表示
Lexeo Therapeutics Inc (LXEO) 最新ニュース
Lexeo Therapeutics Adds Genomic Medicine Leader to Board - TipRanks
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Lexeo Therapeutics (LXEO) director Laura Sepp-Lorenzino files Form 3 - Stock Titan
Lexeo Therapeutics (NASDAQ: LXEO) details 2026 virtual meeting, board elections and pay - Stock Titan
Dr. Laura Sepp-Lorenzino joins Lexeo Therapeutics (LXEO) board and science committee - Stock Titan
Lexeo Therapeutics to Present New Cardiac Gene Therapy Data at ASGCT Annual Meeting 2026 - Quiver Quantitative
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - marketscreener.com
Lexeo brings Friedreich ataxia, heart gene therapy data to Boston - Stock Titan
LXEO SEC FilingsLexeo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
LXEO Stock Chart | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Is Lexeo Therapeutics (LXEO) stock a good candidate for accumulation (Volatility Increases) 2026-04-20Social Buy Zones - UBND thành phố Hải Phòng
Suvretta Capital Management, LLC Increases Stake in Lexeo Therap - GuruFocus
Suvretta, Averill disclose multi-million share holdings in Lexeo Therapeutics (NASDAQ: LXEO) - Stock Titan
What do insiders think about Lexeo Therapeutics (LXEO) Stock | Price at $6.14, Up 2.68%Community Volume Signals - Cổng thông tin điện tử tỉnh Lào Cai
What chart pattern is Lexeo Therapeutics (LXEO) Stock forming | Price at $6.20, Down 3.58%Volume Breakout - UBND thành phố Hải Phòng
Layoff Watch: Is Lexeo Therapeutics Inc backed by strong institutional buying2026 Big Picture & Expert Curated Trade Setup Alerts - baoquankhu1.vn
CEO Change: Is Lexeo Therapeutics Inc attractive for institutional investors2026 Intraday Action & Accurate Intraday Trade Tips - baoquankhu1.vn
Insiders In Lexeo Therapeutics Left Out From 14% Price Rise After Disposing Stock - simplywall.st
What are bearish arguments for Lexeo Therapeutics (LXEO) Stock | Price at $6.28, Down 0.48%Institutional Grade Picks - Cổng thông tin điện tử Tỉnh Sơn La
Insider Sell: Richard Townsend Sells 55,000 Shares of Lexeo Ther - GuruFocus
Lexeo Therapeutics CEO Townsend sells $313k in shares By Investing.com - Investing.com Canada
Lexeo (LXEO) CEO sells 55,000 shares, keeps 340K including RSUs - Stock Titan
[144] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan
If You Invested $1,000 in Lexeo Therapeutics Inc (LXEO) - Stock Titan
Lexeo Therapeutics (LXEO) Price Target Increased by 19.77% to 21.29 - MSN
LXEO Technical Analysis & Stock Price Forecast - intellectia.ai
Published on: 2026-04-02 23:43:24 - baoquankhu1.vn
LXEO Earnings History & Surprises | EPS & Revenue Results | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Oppenheimer Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? - Yahoo Finance
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating - Investing.com
Lexeo Therapeutics 2025 Annual Report: Advancing Genetic Medicine for Cardiovascular Diseases - Minichart
Big Picture: Should I invest in Lexeo Therapeutics Inc before earnings2026 AllTime Highs & Verified High Yield Trade Plans - baoquankhu1.vn
Lexeo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances - TipRanks
Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results - MarketBeat
Lexeo Therapeutics | 10-K: Annual report - Moomoo
Gene therapy advances at Lexeo Therapeutics (NASDAQ: LXEO) target heart disease - Stock Titan
Lexeo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Runway into 2028 as Lexeo (NASDAQ: LXEO) pushes pivotal cardiac gene therapies - Stock Titan
Lexeo Therapeutics : Corporate Presentation March 2026 - marketscreener.com
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - ChartMill
US Market Wrap: Is Lexeo Therapeutics Inc on track to beat earnings2026 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Vanguard realignment leads to separate LXEO holdings reporting (LXEO) - Stock Titan
Aug Mood: Will Lexeo Therapeutics Inc outperform its industry peers2026 Action & Capital Efficient Trading Techniques - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - MSN
Wall Street Recap: Is Lexeo Therapeutics Inc. subject to activist investor interestTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Hedge Fund Moves: Does Lexeo Therapeutics Inc have declining or rising EPSMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-03-22 00:04:32 - baoquankhu1.vn
Lexeo Therapeutics Inc (LXEO) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):